Transcatheter mitral valve implantation (TMVI) using the Edwards FORTIS device.
Publisher DOI
PubMed ID
25256325
Abstract
Transcatheter aortic valve implantation (TAVI) has demonstrated the feasibility of treating valvular heart disease with transcatheter therapy. On the back of this success, various transcatheter concepts are being evaluated to treat other valvular disease, especially mitral regurgitation (MR). The concepts currently approved to treat MR replicate surgical mitral valve repair. However, most of them cannot eliminate MR completely. Similar to TAVI, a transcatheter mitral valve implantation may provide a valuable alternative. The FORTIS transcatheter mitral valve (Edwards Lifesciences, Irvine, CA, USA) is a self-expanding device implanted via a transapical approach. We describe our experience and early results in the first five patients treated on compassionate grounds. We also describe the details of the device, selection criteria and technical details of implantation.
Date Issued
2014-09
Publication Type
Article
Subject(s)
Language(s)
en
Author(s)
Bapat, Vinayak | |
Peterson, Mark D | |
Hancock, Jane | |
Buller, Chris | |
Rajani, Ronal | |
Fam, Neil | |
Kim, Han | |
Redwood, Simon | |
Young, Christopher | |
Munns, Christopher | |
Thomas, Martyn |
Journal
EuroIntervention
Publisher
Europa Digital & Publishing
ISSN
1774-024X
Access(Rights)
metadata.only